The latest price target for Third Harmonic Bio (NASDAQ:THRD) was reported by Morgan Stanley on February 12, 2025. The analyst firm set a price target for $5.00 expecting THRD to rise to within 12 months (a possible 45.77% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Third Harmonic Bio (NASDAQ:THRD) was provided by Morgan Stanley, and Third Harmonic Bio downgraded their equal-weight rating.

The last upgrade for Third Harmonic Bio Inc happened on August 9, 2024 when Morgan Stanley raised their price target to $20. Morgan Stanley previously had an equal-weight for Third Harmonic Bio Inc.

The last downgrade for Third Harmonic Bio Inc happened on February 12, 2025 when Morgan Stanley changed their price target from $20 to $5 for Third Harmonic Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Third Harmonic Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Third Harmonic Bio was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.

While ratings are subjective and will change, the latest Third Harmonic Bio (THRD) rating was a downgraded with a price target of $20.00 to $5.00. The current price Third Harmonic Bio (THRD) is trading at is $3.43, which is out of the analyst’s predicted range.